Loading...
•
Sep 30, 2024
IGM Biosciences Q3 2024 Earnings Report
IGM Biosciences reported financial results for Q3 2024 and provided a corporate update.
Key Takeaways
IGM Biosciences announced a strategic pivot to focus exclusively on autoimmunity during the third quarter. The company's cash runway is expected to fund operations into 2027. Clinical development of Imvotamab and IGM-2644 are underway.
Strategic pivot to focus exclusively on autoimmunity was announced.
Imvotamab trials in rheumatoid arthritis, systemic lupus erythematosus, and myositis are ongoing; initial clinical data is expected by mid-2025.
IGM-2644 is expected to enter clinical study for generalized myasthenia gravis by year-end 2024.
Cash runway is expected to fund operations into 2027.
IGM Biosciences
IGM Biosciences
IGM Biosciences Revenue by Segment
Revenue by Segment
Collaboration Revenue
CapyFin.com Forward Guidance
The Company expects full year 2024 GAAP operating expenses of $215 million to $225 million including estimated non-cash stock-based compensation expense of approximately $40 million, and full year collaboration revenue of approximately $2 million related to the Sanofi agreement. The Company expects to end 2024 with a balance of approximately $180 million in cash and investments and for the balance to enable it to fund its operating expenses and capital expenditure requirements into 2027.
Positive Outlook
- Full year collaboration revenue of approximately $2 million related to the Sanofi agreement is expected.
- Cash balance is expected to fund operating expenses and capital expenditure requirements into 2027.
Challenges Ahead
- Full year 2024 GAAP operating expenses of $215 million to $225 million are expected.
- Estimated non-cash stock-based compensation expense of approximately $40 million is expected.